Compliance as per Regulation 74(5) of the SEBI (Depositories and Participants), Regulations, 2018 for the quarter ended 31st December, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd has submitted a routine compliance certificate for the quarter ended 31st December 2025, as required under Regulation 74(5) of SEBI's Depositories and Participants Regulations, 2018. The company's Registrar and Transfer Agent (RTA), Venture Capital and Corporate Investments Private Limited, has confirmed that all share certificates received for dematerialization during the quarter were properly mutilated, cancelled, and updated in the company's records with NSDL and CDSL as the registered owners within the 15-day deadline. No specific share counts or transactions are disclosed, and this is a standard procedural filing with no business activity involved.
This is a routine administrative compliance filing with no material impact on shareholders, operations, or stock price. Investors can ignore it as part of normal quarterly regulatory housekeeping.